ChemGenex Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
At the moment, chemical genomics is discussed mostly as a hot new approach to drug discovery. Dennis Brown, the founder of ChemGenex Therapeutics Inc. thinks the approach can be applied right now to improve preclinical and clinical drug development--specifically for cancer drugs. His firm is harnessing new methods including gene expression analysis, cellular arrays and information technology to find and assess compounds that already exist. The firm is also leveraging Brown's Rolodex to inform its bioinformatics software. It's gathering insights and tips from medicinal chemists and academic oncologists who've been working with cancer drugs for decades.